Liposomal irinotecan plus temozolomide and bevacizumab for advanced sarcoma
Part of Cancer clinical trials.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and bevacizumab) for people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. The goal is to see if this combination can help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 years or older.
- You have soft tissue sarcoma that has spread or can't be removed and has gotten worse after at least one prior treatment.
- You have at least one tumor that can be measured on scans.
- You are in fairly good health overall (able to do daily activities, with good organ function).
- You have not had treatment with irinotecan, temozolomide, or bevacizumab before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, radiation, and two newer drugs (anlotinib and bempegaldesleukin) for people with advanced soft tissue sarcoma that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
This trial tests a combination of paclitaxel polymer micelles with other drugs for people with advanced bone or soft tissue sarcoma that has worsened after first-line chemotherapy. The goal is to see if this new formulation can help shrink tumors or slow their growth.
This trial tests a new combination of three drugs (zanzalintinib, ipilimumab, and nivolumab) for people with soft tissue sarcoma that has spread. The goal is to see if this combination can shrink or slow the cancer.
This trial tests trabectedin plus ipilimumab and nivolumab in people with advanced soft-tissue sarcoma that has already been treated. It aims to see how well this combination works and how safely it can be given.
Hear when a new Soft Tissue Sarcoma (Excluding GIST) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.